Egetis Therapeutics Management
Management criteria checks 3/4
Egetis Therapeutics' CEO is Nicklas Westerholm, appointed in Jun 2017, has a tenure of 6.92 years. total yearly compensation is SEK5.90M, comprised of 47.5% salary and 52.5% bonuses, including company stock and options. directly owns 0.079% of the company’s shares, worth SEK1.48M. The average tenure of the management team and the board of directors is 6.9 years and 4.8 years respectively.
Key information
Nicklas Westerholm
Chief executive officer
kr5.9m
Total compensation
CEO salary percentage | 47.5% |
CEO tenure | 6.9yrs |
CEO ownership | 0.08% |
Management average tenure | 6.9yrs |
Board average tenure | 4.8yrs |
Recent management updates
Recent updates
Here's Why We're Not Too Worried About Egetis Therapeutics' (STO:EGTX) Cash Burn Situation
May 26We're Keeping An Eye On Egetis Therapeutics' (STO:EGTX) Cash Burn Rate
Dec 21Will Egetis Therapeutics (STO:EGTX) Spend Its Cash Wisely?
Jun 07Is Egetis Therapeutics AB (publ) (STO:EGTX) Trading At A 30% Discount?
Jan 19Egetis Therapeutics AB (publ) (STO:EGTX) Is Expected To Breakeven In The Near Future
Mar 22What Type Of Returns Would Egetis Therapeutics'(STO:EGTX) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?
Feb 15What You Need To Know About Egetis Therapeutics AB (publ)'s (STO:EGTX) Investor Composition
Jan 20Egetis Therapeutics AB (publ) (STO:EGTX) Insiders Increased Their Holdings
Dec 24Analyst Forecasts For PledPharma AB (publ) (STO:PLED) Are Surging Higher
Dec 03When Will PledPharma AB (publ) (STO:PLED) Breakeven?
Dec 03CEO Compensation Analysis
Date | Total Compensation | Salary | Company Earnings |
---|---|---|---|
Dec 31 2023 | n/a | n/a | -kr327m |
Sep 30 2023 | n/a | n/a | -kr319m |
Jun 30 2023 | n/a | n/a | -kr286m |
Mar 31 2023 | n/a | n/a | -kr240m |
Dec 31 2022 | kr6m | kr3m | -kr194m |
Sep 30 2022 | n/a | n/a | -kr148m |
Jun 30 2022 | n/a | n/a | -kr113m |
Mar 31 2022 | n/a | n/a | -kr114m |
Dec 31 2021 | kr5m | kr3m | -kr104m |
Sep 30 2021 | n/a | n/a | -kr147m |
Jun 30 2021 | n/a | n/a | -kr153m |
Mar 31 2021 | n/a | n/a | -kr155m |
Dec 31 2020 | kr4m | kr2m | -kr178m |
Sep 30 2020 | n/a | n/a | -kr127m |
Jun 30 2020 | n/a | n/a | -kr134m |
Mar 31 2020 | n/a | n/a | -kr127m |
Dec 31 2019 | kr3m | kr2m | -kr61m |
Sep 30 2019 | n/a | n/a | -kr61m |
Jun 30 2019 | n/a | n/a | -kr48m |
Mar 31 2019 | n/a | n/a | -kr46m |
Dec 31 2018 | kr3m | kr2m | -kr85m |
Sep 30 2018 | n/a | n/a | -kr95m |
Jun 30 2018 | n/a | n/a | -kr103m |
Mar 31 2018 | n/a | n/a | -kr91m |
Dec 31 2017 | kr1m | kr1m | -kr88m |
Compensation vs Market: Nicklas's total compensation ($USD536.43K) is about average for companies of similar size in the Swedish market ($USD439.67K).
Compensation vs Earnings: Nicklas's compensation has increased whilst the company is unprofitable.
CEO
Nicklas Westerholm (47 yo)
6.9yrs
Tenure
kr5,900,000
Compensation
Mr. Nicklas Westerholm has been the Chief Executive Officer of Egetis Therapeutics AB (publ) (formerly known as PledPharma AB (publ)) since June 16, 2017. Mr. Westerholm has been working in the AstraZeneca...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Chief Executive Officer | 6.9yrs | kr5.90m | 0.079% SEK 1.5m | |
Founder | 18.3yrs | no data | no data | |
Founder | 18.3yrs | no data | no data | |
Founder | 18.3yrs | no data | no data | |
Founder | 18.3yrs | no data | no data | |
Founder | 18.3yrs | no data | no data | |
Chief Financial Officer | 2.9yrs | no data | 0.10% SEK 1.9m | |
Vice President of Operations | 1.2yrs | no data | no data | |
Chief Scientific Officer | no data | kr655.00k | no data | |
Head of IR & Business Development | 2.3yrs | no data | no data | |
General Counsel & Head of Compliance | less than a year | no data | no data | |
Global Head of Marketing & Brand Strategy | 2yrs | no data | no data |
6.9yrs
Average Tenure
61yo
Average Age
Experienced Management: EGTX's management team is seasoned and experienced (6.9 years average tenure).
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Member of Scientific Advisory Board | 5.9yrs | no data | no data | |
Director | 3.1yrs | kr300.00k | 1.07% SEK 20.0m | |
Independent Director | 1.3yrs | no data | no data | |
Director | 3.6yrs | no data | no data | |
Chairman of the Board | 3.1yrs | kr600.00k | 0.097% SEK 1.8m | |
Independent Director | 7.3yrs | kr200.00k | 0.014% SEK 255.2k | |
Independent Director | 7.3yrs | kr200.00k | 0.013% SEK 240.4k | |
Member of Scientific Advisory Board | 5.9yrs | no data | no data | |
Member of Scientific Advisory Board | no data | no data | no data |
4.8yrs
Average Tenure
61yo
Average Age
Experienced Board: EGTX's board of directors are considered experienced (4.8 years average tenure).